These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 19820367)
1. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer. Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367 [TBL] [Abstract][Full Text] [Related]
2. K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Hachisuga T; Tsujioka H; Horiuchi S; Udou T; Emoto M; Kawarabayashi T Br J Cancer; 2005 Mar; 92(6):1098-103. PubMed ID: 15756272 [TBL] [Abstract][Full Text] [Related]
3. K-ras mutation in tamoxifen-related endometrial polyps. Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071 [TBL] [Abstract][Full Text] [Related]
4. Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations. Tsujioka H; Hachisuga T; Hikita S; Ueda T; Yotsumoto F; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S Anticancer Res; 2010 Aug; 30(8):3119-23. PubMed ID: 20871029 [TBL] [Abstract][Full Text] [Related]
5. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Wallén M; Tomás E; Visakorpi T; Holli K; Mäenpää J Cancer Chemother Pharmacol; 2005 Apr; 55(4):343-346. PubMed ID: 15592834 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and the endometrium. Barakat RR Cancer Treat Res; 1998; 94():195-207. PubMed ID: 9587689 [No Abstract] [Full Text] [Related]
7. MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Nagy E; Gajjar KB; Patel II; Taylor S; Martin-Hirsch PL; Stringfellow HF; Martin FL; Phillips DH Br J Cancer; 2014 Jun; 110(12):2874-80. PubMed ID: 24853176 [TBL] [Abstract][Full Text] [Related]
8. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma. Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390 [TBL] [Abstract][Full Text] [Related]
9. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576 [TBL] [Abstract][Full Text] [Related]
10. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma. Jagavkar RS; Shakespeare TP; Stevens MJ Australas Radiol; 1998 May; 42(2):157-8. PubMed ID: 9599835 [No Abstract] [Full Text] [Related]
11. Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis. Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J Int J Gynecol Pathol; 1999 Oct; 18(4):387-91. PubMed ID: 10542949 [TBL] [Abstract][Full Text] [Related]
12. Translesion synthesis past tamoxifen-derived DNA adducts by human DNA polymerases eta and kappa. Yasui M; Suzuki N; Laxmi YR; Shibutani S Biochemistry; 2006 Oct; 45(39):12167-74. PubMed ID: 17002316 [TBL] [Abstract][Full Text] [Related]
13. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Cheng WF; Lin HH; Torng PL; Huang SC Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568 [TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients]. Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485 [TBL] [Abstract][Full Text] [Related]
15. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946 [TBL] [Abstract][Full Text] [Related]
16. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Matsuyama Y; Tominaga T; Nomura Y; Koyama H; Kimura M; Sano M; Miura S; Takashima S; Mitsuyama S; Ueo H; Ohashi Y Ann Oncol; 2000 Dec; 11(12):1537-43. PubMed ID: 11205460 [TBL] [Abstract][Full Text] [Related]
17. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291 [TBL] [Abstract][Full Text] [Related]
18. Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study. Ursic Vrscaj M; Kovacic J; Bebar S; Djurisic A; Fras PA; Robic V Eur J Obstet Gynecol Reprod Biol; 2001 Mar; 95(1):105-10. PubMed ID: 11267730 [TBL] [Abstract][Full Text] [Related]